Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
25.37
-1.79 (-6.59%)
Streaming Delayed Price
Updated: 2:28 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
↗
May 14, 2024
Via
Benzinga
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
↗
May 13, 2024
In the last three months, IBRX outperformed NVDA by over 3x.
Via
Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
↗
May 13, 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Analyst Ratings For Legend Biotech
↗
April 17, 2024
Via
Benzinga
Unveiling 9 Analyst Insights On Legend Biotech
↗
April 01, 2024
Via
Benzinga
Earnings Preview: Legend Biotech
↗
March 08, 2024
Via
Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
↗
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
↗
April 08, 2024
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Legend Biotech
↗
March 07, 2024
Via
Benzinga
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
↗
March 20, 2024
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...
Via
Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
↗
March 18, 2024
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...
Via
Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
↗
March 13, 2024
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...
Via
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
↗
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
March 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Earnings Scheduled For March 11, 2024
↗
March 11, 2024
Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million.
Via
Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
↗
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
↗
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
↗
February 24, 2024
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...
Via
Talk Markets
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
February 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
February 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
↗
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
↗
January 10, 2024
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.
Via
Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
↗
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
